<DOC>
	<DOCNO>NCT00005577</DOCNO>
	<brief_summary>Phase I trial study effectiveness gemcitabine treat child refractory solid tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Gemcitabine Treating Children With Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose gemcitabine child adolescent refractory solid tumor . II . Assess toxicity gemcitabine patient population . III . Determine pharmacokinetic profile gemcitabine male female child adolescent . IV . Assess antitumor activity gemcitabine within phase I study . OUTLINE : This dose escalation study . Patients receive gemcitabine IV 30 minute weekly 2 week . Patients achieve objective response stable disease 3 week may receive additional course therapy every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow week 4 every 6 month death .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor Confirmation make original diagnosis No bone marrow involvement Refractory conventional therapy therapy higher priority accord CCG Phase I/II Priority List PATIENT CHARACTERISTICS : Age : 1 21 Performance status : 02 Life expectancy : At least 2 month Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 ( transfusion independent ) Hemoglobin least 10 g/dL ( transfusion allow ) Bilirubin great 1.5 time normal AST le 2.5 time normal Creatinine great 1.5 time normal OR creatinine clearance radioisotope GFR least 70 mL/min No seizure disorder Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 2 week since prior cytokine therapy recover No prior bone marrow transplantation No 3 prior combination single agent chemotherapy regimens At least 3 week since prior chemotherapy ( 6 week since nitrosoureas ) recover</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>